Evolus Inc (EOLS) financials

NASDAQ · Health Care

$7.35 -2.26% Close Oct 30, 2026 Live

Evolus revenue and earnings by year

Evolus's revenue was $297 million in the fiscal year to December 31, 2025, up 11.6% from the year before. Net income was -$51.6 million, -17.4% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 42.9% a year on average.

RevenueNet income
$0$200M
2019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 7 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue2972662021491005735
Revenue growth11.6%31.8%36.0%49.1%76.3%61.9%—
Gross profit19718213890563827
Gross margin66.3%68.5%68.1%60.4%56.3%67.6%77.1%
Operating income-33-34-49-65-44-153-99
Operating margin-11.0%-12.9%-24.4%-44.0%-44.6%-270.7%-283.3%
Net income-52-50-62-74-47-163-90
Net margin-17.4%-18.9%-30.5%-50.1%-47.0%-288.3%-257.8%
Diluted EPS-$0.80-$0.81-$1.08-$1.33-$0.94-$4.83-$3.18
Free cash flow-51-23-36-88-34-61-98

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EOLS in Markets.

How Evolus makes money

Revenue by segment in the quarter to June 30, 2026, as the company reports it.

SegmentRevenueShare
Product$83.3M99.1%
Services$734K0.9%

See also: EOLS returns

No forecast, no recommendation. This page describes Evolus Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.